Published On : September 2026
A buyer comparing DEL screening providers purely by which discovery stage they support is skipping the distinction that actually determines whether a provider can serve a given program at all: target class.
Within the cellular DNA-encoded library screening market, target class breadth across GPCRs, kinases, protein-protein interactions, transcription factors, ion channels, E3 ligases and novel intracellular targets, not any single target class alone, is what defines this screening category and separates it from narrower biochemical screening approaches.
This page describes five discovery stage categories and seven target class categories strictly as market segments.
It provides no target-validation, biological-mechanism or drug-candidate-efficacy guidance, and makes no claim about the biological validity or druggability of any specific target beyond its category label.
A program targeting E3 ligases generally requires different library design considerations than one targeting a well-characterized GPCR, regardless of which discovery stage the program has already reached.
That is why discovery program leaders experienced in this market evaluate a provider's target class experience before assuming discovery-stage support alone is sufficient.
Five discovery stage categories complete the specification once target class is settled, spanning target identification, hit discovery, hit validation, lead optimization and candidate selection.
For buyers, establishing which target class a program addresses is the starting point for evaluating whether a given DEL screening provider's library and screening technology are actually suited to the work.
For providers, target class breadth across all seven categories widens the addressable share of any discovery partner's program requirements, particularly among partners pursuing multiple difficult-to-drug target categories at once.
Target class experience also shapes sales cycle length, since a provider with demonstrated experience against a novel intracellular target generally moves through scientific assessment faster than one entering that target class for the first time.
Target identification and hit discovery form the two earliest discovery stage categories tracked in this report, both named here as market categories, with this page stating nothing about how either stage's underlying assays are actually run.
Target identification work generally begins before a specific molecule of interest exists, focused instead on establishing which biological target a discovery program should pursue.
Hit discovery follows once a target has been identified, applying DEL screening to surface an initial set of candidate molecules that engage that target for further evaluation.
Both stages typically involve exploratory evaluation and scientific assessment activity before a discovery partner commits to the larger, longer engagement that later discovery stages require.
Buyers at this earliest stage generally value library diversity and scientific expertise over discovery partnership scale, since the program's target class and eventual therapeutic application may still be evolving.
|
BUYER INSIGHT Discovery program leaders evaluating a DEL screening provider for target identification or hit discovery work generally weigh library diversity and scientific expertise more heavily than at later discovery stages, since these earliest stages benefit most from broad coverage across an unproven target. |
Hit validation, lead optimization and candidate selection form the three later discovery stage categories tracked in this report, generally involving a narrower set of molecules than the earlier stages as a program progresses toward a defined candidate.
Hit validation confirms which molecules surfaced during hit discovery genuinely engage the target of interest, a stage this page describes only as a named market category, with no claim made about validation success rates for any provider.
Lead optimization and candidate selection follow once validated hits exist, generally involving closer, longer-term collaboration between a discovery partner and its DEL screening provider than the earlier, more exploratory stages.
The engagement models for this discovery-stage work tend to shift as a program advances: earlier stages more often use fee-for-service screening, while later stages more often move toward discovery partnership programs or co-development agreements, detail covered in this report's engagement model and purchasing pathway breakdown.
For buyers, recognizing which discovery stage a program has reached helps clarify what kind of engagement model and contract negotiation timeline to expect from a prospective DEL screening partner.
A program moving from hit validation into lead optimization frequently narrows from multiple candidate chemical series down to a small number a discovery partner will carry forward, a transition this page treats as a category description rather than a scientific outcome.
GPCRs, kinases and ion channels form three of the seven target class categories tracked in this report, each named here strictly as a market category with no claim made about the biological function or druggability of any specific target.
GPCRs represent one of the most heavily pursued target classes in DEL screening, reflecting their long-standing importance across multiple therapeutic areas tracked in this report.
Kinases are similarly well established as a DEL screening target class, generally benefiting from a large body of existing structural and chemical knowledge that discovery teams can draw on when designing a screening program.
Ion channels represent a more structurally demanding target class, one where several providers position macrocyclic or peptide-based chemistry platforms as better suited than standard small molecule libraries.
Kinase programs in particular often draw on a well-established body of prior structural work, which several providers reference when positioning their target-based DEL screening capability for this target class.
Protein-protein interactions and transcription factors are two of the more difficult-to-drug target classes tracked in this report, both frequently cited as a reason discovery teams turn to DEL screening rather than conventional biochemical screening approaches.
Protein-protein interactions generally present a larger, flatter binding interface than a typical enzyme active site, a structural challenge that several DEL screening providers address through macrocyclic or other larger-format chemistry platforms.
Transcription factors present a related challenge, often lacking the well-defined binding pockets that make more conventional target classes easier to screen against using standard small molecule libraries.
Which therapeutic applications these target classes feed into varies meaningfully, since protein-protein interaction and transcription factor programs concentrate disproportionately in oncology and immunology and inflammation research relative to other target classes, detail covered in this report's therapeutic application and end user segmentation.
For providers, demonstrated experience against protein-protein interactions and transcription factors is generally a meaningful differentiator relative to providers whose track record concentrates on more conventional target classes.
Providers building dedicated macrocyclic or peptide-based library collections for these two target classes are generally responding directly to buyer demand for chemistry platforms suited to larger, flatter binding interfaces.
E3 ligases and novel intracellular targets complete the target class dimension tracked in this report, representing the newest and most difficult-to-drug categories among the seven this report tracks.
E3 ligases have drawn particular discovery-team interest given their role in a growing set of degrader and targeted-protein-modulation research programs, though this page makes no claim about the biological outcome of any such program.
Novel intracellular targets is a catch-all category for target types that do not fit neatly into the other six classes tracked in this report, reflecting how quickly the addressable target universe for DEL screening continues to expand.
Underserved target classes and emerging therapeutic opportunities identified in this report's competitive mapping concentrate disproportionately in these two categories, since fewer established providers have deep track records against E3 ligases and novel intracellular targets relative to more conventional target classes.
For buyers pursuing E3 ligases or novel intracellular targets, confirming a provider's specific target class experience is generally a more useful qualification step than relying on general library size or chemistry platform breadth alone.
Academic consortia and translational medicine centers are disproportionately active in early-stage exploration of novel intracellular targets, reflecting the earlier-stage, more exploratory nature of this target class relative to more established categories such as GPCRs or kinases.
Cellular DEL screening is used across five discovery stage categories: target identification, hit discovery, hit validation, lead optimization and candidate selection, with engagement model and program structure generally differing between the earlier and later stages.
This report tracks seven target class categories: GPCRs, kinases, protein-protein interactions, transcription factors, ion channels, E3 ligases and novel intracellular targets.
E3 ligases and novel intracellular targets are among the newest and most difficult-to-drug categories tracked in this report, and underserved target classes identified in this report's competitive mapping concentrate disproportionately in these two categories.
Target class breadth, not any single target class alone, is what defines this screening category and separates it from narrower biochemical screening approaches, since difficult-to-drug targets such as protein-protein interactions and E3 ligases are a central reason buyers choose DEL screening in the first place.
Hit discovery applies DEL screening to surface an initial set of candidate molecules that engage a target, while hit validation confirms which of those molecules genuinely engage the target of interest before a program advances to lead optimization.